Here is the press release text.

November 01, 2016 06:00 ET
NanoLogix Rapid Bacteria Test Unveiled at CAOG, Wins Judges Choice Award; Technology Published in Journal of Infectious Diseases in Obstetrics and Gynecology

HUBBARD, OH--(Marketwired - Nov 1, 2016) - NanoLogix, Inc. (OTC PINK: NNLX), an innovator in the rapid detection and identification of bacteria, is excited to announce the unveiling of the N-Assay, their new technology for unparalleled rapid, accurate, and sensitive detection and identification of targeted bacteria, including specific determination of antibiotic sensitivity. The technology was presented at the annual meeting of the Central Association of Obstetricians and Gynecologists (CAOG) held in Las Vegas, Nevada from October 27-29. Jonathan Faro, MD, PhD presented the N-Assay research data on the mornings of the 27th and 28th and received the Judges' Choice Gynecology Poster Award for his presentation. On October 30th, the research was published in the Journal of Infectious Diseases in Obstetrics and Gynecology as a peer-reviewed study.

The Journal's open-access publication may be viewed here:
https://www.hindawi.com/journals/idog/2016/5293034/

The N-Assay Diagnostic has applicability for rapid bacteria detection and identification across a broad range of uses in multiple business sectors. Research to date has demonstrated the potential for very rapid detection and identification of any bacteria for which an antibody exists or where one can be developed.

NanoLogix is currently customizing the N-Assay technology for use by a leading multinational medical technology corporation and for one US Federal Agency.